4D USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS
본 발명에서는, 세마포린-4D(SEMA4D)에 또는 그의 플렉신-B1 또는 플렉신-B2 수용체에 특이적으로 결합하는 단리된 결합 분자의 유효량을 신경퇴행성 장애를 갖는 대상에게 투여하는 것을 포함하는, 상기대상에서 증상을 완화하는 방법이 제공된다. Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amoun...
Saved in:
| Main Authors | , , , |
|---|---|
| Format | Patent |
| Language | English Korean |
| Published |
09.08.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | 본 발명에서는, 세마포린-4D(SEMA4D)에 또는 그의 플렉신-B1 또는 플렉신-B2 수용체에 특이적으로 결합하는 단리된 결합 분자의 유효량을 신경퇴행성 장애를 갖는 대상에게 투여하는 것을 포함하는, 상기대상에서 증상을 완화하는 방법이 제공된다.
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors. |
|---|---|
| AbstractList | 본 발명에서는, 세마포린-4D(SEMA4D)에 또는 그의 플렉신-B1 또는 플렉신-B2 수용체에 특이적으로 결합하는 단리된 결합 분자의 유효량을 신경퇴행성 장애를 갖는 대상에게 투여하는 것을 포함하는, 상기대상에서 증상을 완화하는 방법이 제공된다.
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors. |
| Author | SMITH ERNEST S ZAUDERER MAURICE BOWERS WILLIAM J JONASON ALAN |
| Author_xml | – fullname: BOWERS WILLIAM J – fullname: SMITH ERNEST S – fullname: ZAUDERER MAURICE – fullname: JONASON ALAN |
| BookMark | eNqNyssKwjAQQNEsdOHrHwZcF_pQcBubaRtsM2XSuC1F4krSQv1_rOAHuLpwuFuxCmPwG8EnBc4iUAEWG9lWxNpEC161UdqU0FCNuavRQkEMHaPsvmzQMSks0SAvckdQ2hIrZLsX6-fwmv3h1504FtjlVeSnsffzNDx88O_-xmmcpnGSxJdzJrP_rg-i9TIM |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| DocumentTitleAlternate | 신경퇴행성 장애의 치료를 위한 세마포린-4D 결합 분자의 용도 |
| ExternalDocumentID | KR20220110853A |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_KR20220110853A3 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 12:56:36 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English Korean |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_KR20220110853A3 |
| Notes | Application Number: KR20227025504 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220809&DB=EPODOC&CC=KR&NR=20220110853A |
| ParticipantIDs | epo_espacenet_KR20220110853A |
| PublicationCentury | 2000 |
| PublicationDate | 20220809 |
| PublicationDateYYYYMMDD | 2022-08-09 |
| PublicationDate_xml | – month: 08 year: 2022 text: 20220809 day: 09 |
| PublicationDecade | 2020 |
| PublicationYear | 2022 |
| RelatedCompanies | VACCINEX, INC |
| RelatedCompanies_xml | – name: VACCINEX, INC |
| Score | 3.3695912 |
| Snippet | 본 발명에서는, 세마포린-4D(SEMA4D)에 또는 그의 플렉신-B1 또는 플렉신-B2 수용체에 특이적으로 결합하는 단리된 결합 분자의 유효량을 신경퇴행성 장애를 갖는 대상에게 투여하는 것을 포함하는, 상기대상에서 증상을 완화하는 방법이 제공된다.
Provided herein are... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | 4D USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220809&DB=EPODOC&locale=&CC=KR&NR=20220110853A |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fT8IwEL4gGvVNUeMPNE00e1tkdIB7WMxYO5mwjXSD8EbWCYnRAJEZ_32vA5Qn3tpr0rSXfr1e-90V4EHlh6Fo53X0f2q6mWapbjVlTU9b2XQicUlZhop3DsJmZ2C-jhqjEnxuYmGKPKE_RXJERFSGeM-L_Xrxf4nFCm7l8lG-o2j-7CU209becb2OByBLY22b9yMWuZrr2l2hhWLVpijvDerswT4epFsKD3zYVnEpi22j4p3AQR_7m-WnUPqYV-DI3fy9VoHDYP3kjcU1-pZnIExGBjEnkUdiHjj9TiT8UEdh2w-ZH76QIOpxd9DjMUHfjiSCO4kSh4qux_iKpZb4Q06YH6Pzx0V8DvceT9yOjoMb_-li3BXbM6EXUJ7NZ5NLIKZRN-Sb-uHEyEw6TRGpkkqVT47SlnySV1Dd1dP17uYbOFbVgvlmVaGcf31PbtEa5_KuUOIvxe6FRA |
| link.rule.ids | 230,309,783,888,25576,76876 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8gGvFNUeMHahPN3hbZOsA9EANr5yb7INsgvJF1QmI0QGTGf9_rAOWJt-YuubRNf71e-7srwIOsD0PRz6sY_9RVI81S1WyKupq2sulE4JIyNZnv7AdNZ2C8jhqjEnxucmGKOqE_RXFERFSGeM-L_Xrxf4nFCm7l8lG8o2j-bCdtpqyjY13HA5CpsG6b90MWWopltXuREkQrnaS8N2hnD_bxkN2SeODDrsxLWWw7FfsYDvpob5afQOljXoWKtfl7rQqH_vrJG5tr9C1PITIYGcSchDaJud_pO2HkBioKu27A3OCF-KHHrYHHY4KxHUki3kmkOJB0PcZXLLXEHXLC3BiDPx7FZ3Bv88RyVOzc-G8uxr1oeyT0HMqz-WxyAcTQdE28yR9OtMyg0xSRKqiQ9eQobYkncQm1XZaudqvvoOIkvjf23KB3DUdSVbDgzBqU86_vyQ165lzcFhP6CzIuiDc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=4D+USE+OF+SEMAPHORIN-4D+BINDING+MOLECULES+FOR+TREATING+NEURODEGENERATIVE+DISORDERS&rft.inventor=BOWERS+WILLIAM+J&rft.inventor=SMITH+ERNEST+S&rft.inventor=ZAUDERER+MAURICE&rft.inventor=JONASON+ALAN&rft.date=2022-08-09&rft.externalDBID=A&rft.externalDocID=KR20220110853A |